Home Ingredients Pramiracetam (Pramistar)
Cognitive

Pramiracetam (Pramistar)

Synthetic — high-affinity choline uptake racetam
Evidence Level
Preliminary
3 Clinical Trials
5 Documented Benefits
1/5 Evidence Score

Pramiracetam is a potent, fat-soluble racetam studied for memory and focus and considered one of the stronger racetams by milligram. Like other racetams, it is not an approved dietary supplement or drug in the United States, though it has been studied clinically, and evidence in healthy people is limited. Community and research doses are often around 300 to 600 mg per day, split and taken with food. Pramiracetam is generally reported as tolerated short-term, with possible headache that some address by taking choline alongside; long-term and self-directed use is uncertain, so consult a healthcare professional.

Studied Dose Standard 600 mg BID (1,200 mg/day); AD trials 400-1,500 mg/day; post-TBI/ECT 1,200 mg/day; nootropic 600-1,200 mg/day.
Active Compound Pramiracetam (N-(2-(diisopropylamino)ethyl)-2-(2-oxopyrrolidin-1-yl)acetamide; CI-879, Neupramir, Pramistar); diisopropylamine derivative of piracetam.

Benefits

Senile cognitive disorders (Italian approval — limited evidence)

Pramiracetam is approved in Italy as Pramistar for treatment of senile cognitive disorders. Approval is based primarily on older Italian trials. Mechanism: high-affinity choline uptake enhancement. Critical caveat: rigorous large-scale RCTs supporting efficacy are limited. Italian regulatory approval reflects older European pharmacological standards and would not necessarily meet modern FDA standards.

Supported by Trial 2, Trial 3

Post-traumatic brain injury cognitive recovery (small studies)

A clinical trial in 4 patients with cognitive problems following head injury (extremely small study), plus some Italian and Russian studies in post-TBI cognitive rehabilitation. Limited rigorous evidence; small samples, heterogeneous methods.

Supported by Trial 3

ECT adjunct for major depression (orphan designation withdrawn)

Pramiracetam was pursued as an adjunct to electroconvulsive therapy in major depression: FDA orphan designation was obtained in 1991, then withdrawn when the company abandoned the drug. Demonstrates a failed clinical development trajectory.

Supported by Trial 1, Trial 3

Alzheimer's disease (Warner-Lambert abandoned Phase II)

Phase II Alzheimer's disease clinical trials were conducted. Results were mixed, leading the company to abandon the indication. Important counter-evidence: a pharmaceutical company with substantial resources concluded the drug was not commercially viable for AD. Honest framing: pramiracetam's failed AD development is significant.

Supported by Trial 1

High-affinity choline uptake enhancement (mechanism)

Animal studies show pramiracetam enhances high-affinity choline uptake in the hippocampus, supporting acetylcholine synthesis and cholinergic neurotransmission. This effect distinguishes pramiracetam from other racetams. Mechanism plausible for cognitive enhancement but human translation unclear.

Supported by Trial 3, Trial 2

Mechanism of action

1

High-affinity choline uptake (HACU) enhancement

Pramiracetam selectively enhances high-affinity choline uptake in hippocampus — rate-limiting step in acetylcholine synthesis. Mechanism distinct from piracetam (cell membrane fluidity) and aniracetam (AMPA modulation). Theoretical basis for cognitive enhancement via increased ACh availability for synthesis.

2

Lipophilicity enables BBB penetration

Diisopropylamine substitution makes pramiracetam dramatically more lipophilic than piracetam. Higher CNS concentrations achievable; faster onset. Potency ~30x piracetam by weight allows much smaller effective doses.

3

Cerebral blood flow increase (limited evidence)

Some animal evidence suggests pramiracetam increases cerebral blood flow and oxygen utilization. Mechanism may relate to membrane effects or vasoactive properties. Less robust than piracetam's microcirculation effects.

4

NO/cGMP pathway modulation (preclinical)

Limited preclinical evidence for nitric oxide / cyclic GMP signaling modulation. Mechanism poorly characterized; may contribute to cognitive effects but speculative.

Clinical trials

1
Warner-Lambert Phase II Alzheimer's Trials (failed development)
PubMed

Pharmaceutical company-sponsored Phase II clinical trials (Warner-Lambert / Parke-Davis, late 1980s-1990s).

Alzheimer's disease patients in Phase II trials. Sample sizes and specific designs not fully published in peer-reviewed literature.

Mixed results — Warner-Lambert abandoned Alzheimer's indication based on Phase II outcomes. Drug then licensed to Cambridge Neuroscience (US) for ECT adjunct indication and Menarini (Europe) for dementias. CNI eventually abandoned drug; orphan designation withdrawn. Failed clinical development trajectory is significant negative evidence — substantial pharmaceutical resources concluded efficacy insufficient for commercial development.

2
Italian Senile Cognitive Disorders Trials (Pramistar Approval Basis)
PubMed

Older European clinical trials supporting Italian regulatory approval as Pramistar.

Italian patients with senile cognitive disorders. Various trial designs.

Approval as Pramistar (Italy, Menarini) for senile cognitive disorders based on these trials. Specific publications less prominent in international literature. Italian regulatory standards in approval era less stringent than current FDA. Demonstrates that some European approvals may reflect older or smaller evidence bases than FDA standards would accept.

3
Cambridge Neuroscience Head Injury Trial (n=4)
PubMed

Small clinical trial conducted by Cambridge Neuroscience Inc. (CNI) for post-TBI cognitive recovery.

4 patients with cognitive problems following head injury — extremely small sample.

Extremely limited sample size. Some signal of efficacy reported but cannot draw conclusions from n=4. CNI later abandoned pramiracetam development. Demonstrates the limited rigorous human evidence base for pramiracetam outside dated Italian senile cognitive disorder approval studies.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; safety profile similar to other racetams.
Headache (more frequent than other racetams in some users).
Anxiety, restlessness.
GI upset (nausea, abdominal discomfort).
Insomnia.
Pregnancy/lactation: avoid.
Long-term safety beyond 1 year: limited data.
Failed pharmaceutical development is significant safety/efficacy signal.

Important Drug interactions

Cholinergic medications: theoretical additive effects.
Anticoagulants: theoretical mild antiplatelet effects.
Stimulants: theoretical additive CNS effects.
Most medications: compatible at typical doses.
Limited interaction data due to small clinical research base.

More Cognitive Ingredients

Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Cognitive
Longvida® Optimized Curcumin (Verdure Sciences)
Longvida® is a patented curcumin extract developed by Verdure Sciences using SLCP™ (Solid…
Cognitive
CurQfen® (Curcumin-Fenugreek FenuMat — Akay Bioactives)
CurQfen® is a patented curcumin complex from Curcuma longa rhizomes formulated with FENUMA…
Cognitive
Ashwagandha
Ashwagandha (Withania somnifera) is an adaptogenic herb from Ayurvedic tradition, widely u…

Explore Other Ingredients

Cognitive
Bacopa Monnieri
Bacopa monnieri (Brahmi) is a cornerstone herb in Ayurvedic medicine with over 3,000 years…
Cognitive
Citicoline
Citicoline (CDP-choline) is a naturally-occurring intermediate in phosphatidylcholine bios…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…

Frequently asked questions about Pramiracetam (Pramistar)

What is pramiracetam?

Pramiracetam is a potent, fat-soluble racetam studied for memory and focus. Like other racetams, it is not an approved dietary supplement or drug in the US, though it has been studied clinically.

What is pramiracetam used for?

It is researched and used for memory, focus, and learning, and is considered one of the stronger racetams by milligram. Evidence in healthy people is limited.

How much pramiracetam is used?

Community and research doses are often around 300 to 600 mg per day, split, taken with food since it is fat-soluble. Quality and legal status vary, so caution is warranted.

Is pramiracetam safe?

Short-term use is generally reported as tolerated, with possible headache; choline is sometimes taken alongside. Long-term and self-directed use is uncertain, and it is not an approved US supplement, so consult a healthcare professional.

What is the recommended dosage of Pramiracetam?

The clinically studied dose is Standard 600 mg BID (1,200 mg/day); AD trials 400-1,500 mg/day; post-TBI/ECT 1,200 mg/day; nootropic 600-1,200 mg/day. Always follow the product label and check with a healthcare provider for personal advice.

Is Pramiracetam safe, and does it have side effects?

For most healthy adults, Pramiracetam is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; safety profile similar to other racetams. Headache (more frequent than other racetams in some users). It may also interact with some medications. Pramiracetam is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Pramiracetam interact with any medications?

Possible interactions include: Cholinergic medications: theoretical additive effects. Anticoagulants: theoretical mild antiplatelet effects. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Pramiracetam?

NutraSmarts rates the evidence for Pramiracetam as Preliminary (1 out of 5). It is backed by 3 clinical trials and 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. McLean A Jr, Cardenas DD, Burgess D, Gamzu E Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia Brain Injury. 1991;5(4):375-80. doi:10.3109/02699059109008110.PubMedUsed to support: Placebo-controlled clinical trial of pramiracetam sulfate (400 mg three times daily) in young males with memory deficits from TBI or anoxia; found clinically significant improvements in delayed recall measures that persisted through 18-month open-label extension; supports 'Post-traumatic brain injury cognitive recovery (small studies)' benefit. Small sample size; limited generalizability.
  2. Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam Neurology. 1991;41(4):570-4. doi:10.1212/wnl.41.4.570.PubMedUsed to support: Randomized clinical trial of pramiracetam in Alzheimer's disease patients; found modest symptomatic improvement in cognitive performance measures; supports 'Alzheimer's disease' research context and 'Senile cognitive disorders' benefit claim; authors note limited overall efficacy. Represents the type of preliminary evidence behind the abandoned Warner-Lambert AD program.